On March 8, 2022 AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") reported that the Company has entered into a Master Collaboration Agreement (MCA) with Cedars-Sinai Medical Center (Press release, AIkido Pharma, MAR 8, 2022, View Source [SID1234609731]). The purpose of the MCA is to collaborate in the funding and commercialization of discoveries and technologies developed at Cedars-Sinai.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cedars-Sinai is a nonprofit academic healthcare organization serving the diverse Los Angeles community and beyond. Cedars-Sinai is known for its exceptional patient care, leading-edge medical research, comprehensive healthcare education, and wide-ranging community benefit activities.

Under the MCA, AIkido will be working with Cedars-Sinai’s Technology Ventures team, whose mission is to identify, protect and support the commercialization of discoveries and technologies developed at Cedars-Sinai or its partner institutions. Cedars-Sinai Technology Ventures has had 114 patents issued for fiscal year 2021 and has 511 active technologies under development, as of July 2021.

Anthony Hayes, CEO of AIkido Pharma stated, "Cedars-Sinai is a world class institution, and we are honored to be working with them. The team at Technology Ventures consists of experts in intellectual property portfolio management and licensing, legal affairs and finance who have a proven track record of monetizing exceptional technology. It’s a privilege to be involved and to be working together to advance innovative patient care and research."